Abbvie Inc ABBV

$292.82 -1.73 (-0.59%)

Valuation

Market cap
520,651,264,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
23.00
P/E (forward)
21.10
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
3,950,000
Avg volume
4,934,646
Day's range
$291.00 – $294.06
Shares out
1,767,616,000
Stochastic %K
54%
Beta
0.20
Analysts
Moderate Buy
Price target
$311.30

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

AdamBrennan2 Nov 18, 11:22 AM
c4 therapeutics $CCCC is a biotech building drugs that destroy disease-causing proteins instead of just blocking them, and it has no product on the market yet but look at who is around it: merck kgaa, roche, pfizer and betta pharma are all partners or suppliers in the picture big names are already working with a company that has no sales to me this looks more like a lab with serious partners than a lonely bet, though the drugs still have to work $ABBV $AMGN $GILD $VRTX
1 replies
openclassaction2 Nov 18, 10:35 AM
$ABBV a suit alleges abbvie failed to warn that juvederm fillers can cause delayed granulomas, per open class actions. lawsuit stage, nothing to claim. seems like the warning label was the missing feature
0 replies
AdamBrennan2 Nov 18, 6:47 AM
everyone thinks a biotech like bridgebio $BBIO is just a lab burning cash on ideas, but the picture shows a company already selling a drug acoramidis is sold straight to patients in the us, and bayer and alexion carry it in europe and japan so the heavy lifting abroad is done by partners, while the lab work leans on outside research and manufacturing firms to me that looks like a lean model, but the picture shows one approved drug carrying the load $ABBV $AMGN $GILD $VRTX
1 replies
Techdamentals Nov 18, 4:11 AM
The S&P 500 fell 1.03% to 7,340.53 on Tuesday, November 17, 2026, its lowest close since July, and Nvidia reported after the close. One number from $ABBV's latest report: net revenues rose 10.3% to $17.404 billion in the quarter ended September 30, 2026, from $15.776 billion a year earlier. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator lays out revenue, margins, cash and debt from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. See the fundamentals below 👇 https://techdamentals.com/v3/ABBV?ref=st
0 replies
55X_ROI_Q1_2026 Nov 18, 3:53 AM
$SLS GPS +KEYTRUDA MOS 18.4 Months P2 vs IMGN 16.46 Months A brief reminder, once GPS and MRK reported the Phase 2 GPS +Keytruda combination trial data for Platinum Resistant/Refractory Ovarian Cancer Patients - 18.4 Month Median OS, in End stage, that was better than ​IMGN's Soraya P3 - 16.46 Month MOS in the same Setting - $ABBV Paid $10B for IMGN based on LESSER DATA than What GPS Reported .. $MRK Dr. Julie Cohen, in co-authoring the P2 Published data, stated, GPS would Work EVEN Better in an earlier Macroscopic Setting. GPS +KEY MOS 18.4 Months P2 vs IMGN / 16.46 Months //
0 replies
robcarroll Nov 17, 10:08 PM
$SLS and $ABBV https://tickerhall.com/p/116298260058644480
2 replies
rejuven8 Nov 17, 9:43 PM
$SLS this is an Abbvie $ABBV buyout candidate to replace their lost revenue of Veneteclax upcoming. You tell the doctor “no toxicity and 50% of patients live longer” that’s a no brainer.
1 replies
55X_ROI_Q1_2026 Nov 17, 9:42 PM
$SLS $330M in capital costs to date. A nice Tax Write off for $ABBV . . . . . . . . $200M Rare Priority Pediatric Review Voucher Cash on Hand $277M (post ) $IMGN Raised cash on the back of its P3 in PR/roc before it was bought for $10B .... In May of 2023 / before the Buyout in Dec //// ImmunoGen Announces Proposed Public Offering of ... 2023-05-03-ImmunoGen-Announces May 3, 2023 — it intends to offer and sell, $200 million of shares of its common stock in an underwritten public offering. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 replies